HomeCoronary diseaseAcute coronary syndromes

Acute coronary syndromes

ACC 2022 | PROMPT-HF

Patients with cardiac failure with reduced ejection fraction (HFrEF) are sub treated when you look at guideline-directed...

ACC 2022 – Complete Trial QoL: Complete Revascularization in STEMI

The COMPLETE study has shown complete revascularization in STEMI reduces cardiovascular mortality or new AMI, which generated...

STEMI: Can We Omit Stenting?

The recommended treatment for ST elevation acute myocardial infarction (STEMI) is early PCI, typically stenting. However, stent...

REVERSE-IT | Bentracimab: Progress on the Antidote for Ticagrelor in Emergency Scenarios

Optimizing an antiplatelet therapy after an acute coronary syndrome (ACS) aims at reducing the major adverse cardiac...

Is Coronary Revascularization Useful in Renal Transplant Candidates?

Coronary artery disease is the main cause of death in patients with functioning renal transplant, reaching 30%,...

Ticagrelor Monotherapy after 3 Months: Is the Current Strategy Worth Changing?

Dual antiplatelet therapy (DAPT) after PCI with DES has shown noticeable reduction of thrombotic events, especially in...

Abbreviated DAPT in ACS: The End of Clopidogrel Monotherapy?

Compared with patients with chronic coronary syndromes, patients with acute coronary syndromes (ACS) are more likely to...

Zwolle Score: Can a Risk Score Decide Where STEACS Patients Should Stay?

The mortality of ST-segment elevation acute coronary syndromes (STEACS) has decreased thanks to improved reperfusion times (fibrinolysis...